FDA says positives outweigh risks on Acadia’s Parkinson’s psychosis drug
pharmafile | March 30, 2016 | News story | Research and Development, Sales and Marketing | FDA, Parkinson's, Parkinsons, acadia, nuplazid, pimavanserin, psychosis
Acadia Pharmaceuticals (NASDAQ: ACAD) has announced a positive result from the US Food and Drug Administration (FDA) concerning Nuplazid (pimavanserin) for the treatment of psychosis related to Parkinson’s disease.
A panel of the FDA’s Psychopharmacologic Drugs Advisory Committee voted 12 to 2 that the benefits of Nuplazid outweighed the potential risks of treatment. The FDA has granted the new drug application for Nuplazid priority review status and has designated the drug for the treatment of psychosis associated with Parkinson’s disease as a breakthrough therapy.
The drug itself is a small molecule that is a selective serotonin inverse agonist preferentially targeting receptors that play an important role in psychosis. Approximately 40% of patients with Parkinson’s disease suffer from the related psychosis, which is characterised by hallucinations and delusions, a diminished quality of life, and significant caregiver burden.
Steve Davis, president and CEO at Acadia, comments: “We are very encouraged by the Committee’s positive vote today and look forward to working with the FDA as it completes its review of Nuplazid. If approved by the FDA, Nuplazid would be the first drug indicated to treat psychosis associated with Parkinson’s disease.”
Acadia’s drug has been highlighted as a potential blockbuster in the making. Recently, we revealed the results of a Thomson Reuters report which predicted it could achieve sales of $1.4 billion by 2020.
Sean Murray
Related Content
MRM Health’s ulcerative colitis treatment receives FDA Investigational New Drug clearance
Microbial Resource Management (MRM) Health has announced that its lead programme, MH002, has received Investigational …
Complement Therapeutics’ geographic atrophy treatment receives FDA Fast Track designation
Complement Therapeutics has announced that CTx001, its gene therapy treatment for geographic atrophy (GA) secondary …
Johnson & Johnson submits robotic surgical system for De Novo classification
Johnson & Johnson has announced the submission of its Ottava Robotic Surgical System for De …
